Table 2

Successful virus clearance from LCMV-WE carrier mice requires d60 immune B cells

Combination of transferred lymphocytes* (CD4/CD8/B)Virus titerNAb titers
BloodBrainSpleenKidney
Unseparated spleen cells (d60)<1.7<2.0<2.04.7 ±0.53/3
d8/d60/d60<1.7<1.8<2.03.8 ± 0.43/3
d8/—/d60<1.7<2.0<2.04.6 ± 0.33/3
d60/d8/d83.9 ± 0.34.8 ± 0.54.5 ± 0.55.5 ± 0.60/3
d60/—/d84.2 ± 0.54.7 ± 0.24.2 ± 1.15.7 ± 0.40/3
  • * Spleen cells from mice infected i.v. with 200 pfu of LCMV-WE either 8 or 60 days previously were depleted of CD4+ or CD8+ T cells or B cells or positively selected for CD4+ or CD8+ T cells or B cells using magnetic beads. Then, 5 × 106 CD4+ T cells, 5 × 106 CD8+ T cells, and 1 × 107 B cells from d8 or d60 immune spleens were injected in various combinations (cell order shown is CD4/CD8/B cells) into LCMV-WE-carrier mice according to the experimental setups listed in the table. 

  • Virus titers are expressed as plaque-forming units per milliliter of blood or gram of organ (log10) on day 40 after cell transfer and are means ± SEM of three mice. The experiments were repeated at least three times with similar results. 

  • Neutralizing antibody (NAb) titers were monitored 15–30 days after adoptive transfer, and numbers of mice displaying titers >2 log2 per total number of mice are given in the table.